Menu

Turning Tumor Cells Against Cancer

In mice, cancer cells genetically modified to express an anticancer cytokine home to tumors and can reduce their growth. 

Feb 8, 2016
Anna Azvolinsky

Schematic of the process of tumor cell self-targetingUNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, ELEONORA DONDOSSOLAFive years ago, scientists at the Memorial Sloan Kettering Cancer Center in New York City showed that circulating tumor cells (CTCs) could both colonize new metastases and travel back to their tumors of origin. Taking advantage of this bidirectional CTC movement, researchers at the University of New Mexico and their colleagues injected mice with CTCs that were genetically modified (GM) to express an anticancer cytokine. In a mouse study, the researchers found that these GM CTCs were able to home to tumors and release the cytokine, leading to decreased tumor growth. The results, published today (February 8) in PNAS, suggest cancer cells may be useful tools for anticancer therapies.

“This paper is an elegant example of thinking outside the box,” said Elizabeth Comen, a medical oncologist and researcher at Memorial Sloan Kettering who was not involved with the work. “To leverage the cancer cell’s powerful ability to travel all over the body against tumors is fascinating.”

“The idea is interesting and audacious,” Joan Massagué of Memorial Sloan Kettering, who was a coauthor on the 2009 paper showing bidirectional CTC movement but was not involved in the present study, wrote in an email to The Scientist.

The University of New Mexico’s Wadih Arap, Renata Pasqualini, and their colleagues engineered murine tumor cells derived from three tumor types—melanoma, lung, and mammary adenocarcinoma—to express and release tumor necrosis factor alpha (TNF-α). TNF-α is a cytokine shown to damage tumor vasculature, among other anticancer activities. “It’s extremely potent as an anticancer agent but also extremely toxic, which makes it a perfect payload to use as a targeted agent,” Pasqualini told The Scientist. “When given only locally, the efficacy is increased and the toxicity decreases.”

When any of the three types of TNF-α–expressing CTCs were injected into immunocompetent mice with implanted mammary adenocarcinoma, the tumors’ growth rates were reduced. Challenging the mice that had the TNF-α–expressing tumor cells in circulation with additional, cancer-initiating tumor cells appeared to prevent the formation of tumors, suggesting that the GM CTCs helped protect mice from new tumors. The researchers also observed that the TNF-α–expressing CTCs did not propagate in vivo. “The cells that are producing TNF eventually die, so we are not injecting cells likely to backfire,” which could fuel cancer growth, said Pasqualini. “They are surrounded by TNF-α—booby-trapped, so to speak.”

When injected into mice with the corresponding primary tumors, each of the three TNF-α–expressing CTC lines resulted in inhibition of tumor growth by 50 percent to 65 percent, the researchers reported.  Injecting the GM CTCs into the bloodstream appeared more effective than subcutaneous administration, they noted.

To test whether the GM CTCs might impact metastasis, the researchers first injected standard tumor cells into mice with growing primary tumors. Normal CTCs formed lung metastases, but when the mice with metastatic tumors were injected with the GM CTCs, the researchers observed fewer metastatic colonies formed than in control animals.

“While so many scientists are trying to design nanoparticles delivery agents to bring drugs selectively to tumors, [the authors] have capitalized in the inherent ability of certain tumor cells to "’elf seed,’” Bruce Zetter, who studies the mechanisms of tumor progression at Harvard and was not involved in the work, told The Scientist in an email. “It’s appealing that the tumor cells should be able to find their counterparts both in primary and in secondary tumor sites.”

Using TNF-α as a “warhead” was a good first choice, wrote Zetter. “TNF-α is probably working here principally as an antivascular agent. . . . One can imagine that others will employ many different types of agents over time.”

Comen noted that the challenge, now, will be to make sure the GM CTCs don’t contribute to metastasis. To Arap’s mind, irradiatiating the engineered cells—so they cannot divide—is one potential solution. (In the present study, the researchers showed that irradiated GM CTCs inhibited tumor growth, but not to the same extent as nonirradiated GM CTCs did.)

Going forward, Massagué said he would like to see an attempt to target an endogenous tumor in mice with modified CTCs derived from the same tumor. “If that experiment worked, the [cancer] field would get excited,” he told The Scientist.

E. Dondossola et al., “Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors,” PNAS, doi:10.1073/pnas.1525697113, 2016.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.